A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

586

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: KarXT
DRUG: KarX-EC
OTHER: Placebo

Sponsor

Bristol-Myers Squibb